![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Humedix has secured certain exclusive distribution rights in Korea for products that are commercialized from Kineta's pipeline currently under development including KVA12.1.
Lead Product(s): KVA12.1
Therapeutic Area: Oncology Product Name: KVA12.1
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Kineta
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 04, 2021